Saturna Capital CORP trimmed its position in GlaxoSmithKline plc (NYSE:GSK) by 14.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 354,507 shares of the pharmaceutical company’s stock after selling 57,793 shares during the period. Saturna Capital CORP’s holdings in GlaxoSmithKline were worth $14,393,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GSK. Proficio Capital Partners LLC increased its position in shares of GlaxoSmithKline by 16.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after acquiring an additional 457 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its position in GlaxoSmithKline by 1.9% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 64 shares during the period. FTB Advisors Inc. grew its position in GlaxoSmithKline by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after purchasing an additional 539 shares during the period. Quadrant Capital Group LLC grew its position in GlaxoSmithKline by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock worth $162,000 after purchasing an additional 148 shares during the period. Finally, Parallel Advisors LLC grew its position in shares of GlaxoSmithKline by 93.4% during the 2nd quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock valued at $164,000 after acquiring an additional 1,955 shares during the period. 9.83% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently commented on GSK shares. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. UBS upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating and raised their target price for the company from $35.04 to $35.85 in a research report on Monday, November 27th. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Wednesday, October 18th. Argus restated a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline in a research report on Thursday, August 31st. Finally, Investec cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline presently has a consensus rating of “Hold” and an average price target of $39.71.

In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 10.00% of the company’s stock.

Shares of GlaxoSmithKline plc (NYSE:GSK) traded down $0.14 during trading on Wednesday, reaching $34.72. 1,896,296 shares of the company were exchanged, compared to its average volume of 3,498,092. The stock has a market cap of $86,076.94, a price-to-earnings ratio of 12.41, a PEG ratio of 1.94 and a beta of 0.98. GlaxoSmithKline plc has a 1 year low of $34.72 and a 1 year high of $44.53. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44.

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be paid a $0.5037 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 dividend on an annualized basis and a yield of 5.80%. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 163.12%.

WARNING: “Saturna Capital CORP Cuts Position in GlaxoSmithKline plc (GSK)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/06/saturna-capital-corp-cuts-position-in-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.